Oppenheimer reiterates Tectonic stock rating after trial data

Oppenheimer has reaffirmed its Outperform rating and $80.00 price target for Tectonic Therapeutics Inc. (TECX) shares after analyzing competitor trial results. The firm's confidence in TECX's TX45 was bolstered by AstraZeneca's LUMINARA Phase 2b readout, which demonstrated efficacy in chronic relaxin agonism for heart failure. Oppenheimer explained that the recent selloff of TECX shares was due to built-up expectations and lingering skepticism from prior relaxin failures, rather than any fundamental shift in the TX45 narrative.

The stock experienced a 20.6% decline over the past week, currently trading at $29.94, but remains up 43.5% year-to-date. TECX is operating with more cash than debt on its balance sheet. The next major test for Tectonic will be the APEX Phase 2 trial of TX45, focusing on pulmonary hypertension associated with heart failure, with top-line data expected in early 2027.